Filing Flows › Boston Scientific (BSX) › Q3 2026 › vs Q3 2025
Boston Scientific (BSX) Q3 2026 vs Q3 2025 (year over year)
Boston Scientific's revenue rose $73.0M (+1%) from $5.1B in Q3 2025 to $5.1B in Q3 2026. The biggest changes: Interventional Cardiology & Vascular Therapies +$138M (+12%); Electrophysiology −$49.0M (-6%); Neuromodulation +$38.0M (+13%). Gross margin 66.7% against 69.9% (-3.2 pts).
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 66.7% | 69.9% | -3.2 pts |
| Operating margin | 16.1% | 20.7% | -4.6 pts |
| Net margin | 11.3% | 14.9% | -3.6 pts |
| Free cash flow margin | 16.9% | 22.9% | -6.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.3B | $1.1B | $138M | +12% |
| Electrophysiology | $816M | $865M | −$49.0M | -6% |
| Endoscopy | $741M | $747M | −$6.0M | -0.8% |
| Urology | $661M | $682M | −$21.0M | -3% |
| Cardiac Rhythm Management | $568M | $578M | −$10.0M | -2% |
| Watchman | $482M | $512M | −$30.0M | -6% |
| Neuromodulation | $331M | $293M | $38.0M | +13% |
| Interventional Oncology & Embolization | $267M | $253M | $14.0M | +6% |
| Revenue | $5.1B | $5.1B | $73.0M | +1% |
| Gross profit | $3.4B | $3.5B | −$114M | -3% |
| Cost of revenue | $1.7B | $1.5B | $187M | +12% |
| Operating profit | $828M | $1.0B | −$220M | -21% |
| Operating expenses | $2.6B | $2.5B | $106M | +4% |
| Pre-tax earnings | $733M | $939M | −$206M | -22% |
| Other expense, net | $95.0M | $109M | −$14.0M | -13% |
| Research & development | $520M | $514M | $6.0M | +1% |
| SG&A | $1.7B | $1.7B | −$58.0M | -3% |
| Other operating costs | $397M | $239M | $158M | +66% |
| Net earnings | $580M | $755M | −$175M | -23% |
| Income tax | $153M | $183M | −$30.0M | -16% |
| Depreciation & amortization | $361M | $342M | $19.0M | +6% |
| Share-based compensation | $72.0M | $79.0M | −$7.0M | -9% |
| Working capital & other | $35.0M | $167M | −$132M | -79% |
| Operating cash flow | $1.0B | $1.3B | −$295M | -22% |
| Free cash flow (OCF − capex) | $868M | $1.2B | −$294M | -25% |
| Capital expenditures | $180M | $181M | −$1.0M | -0.6% |
Questions
How much did Boston Scientific's revenue grow year over year in Q3 2026?
Boston Scientific's revenue rose $73.0M (+1%) from $5.1B in Q3 2025 to $5.1B in Q3 2026.
What drove Boston Scientific's revenue change in Q3 2026?
Interventional Cardiology & Vascular Therapies +$138M (+12%); Electrophysiology −$49.0M (-6%); Neuromodulation +$38.0M (+13%).